Stryker公司击败了收入估计,提高了2025年的指导,并增加了股息,尽管内幕销售。 Stryker Corp. beat earnings estimates, raised 2025 guidance, and boosted dividend, despite insider sales.

Stryker公司报告第二季度收入强劲,EPS收入为3.13美元,收入为60.2亿美元,同比增长11.1%,超过预期。 Stryker Corporation reported strong second-quarter earnings, with $3.13 EPS and $6.02 billion in revenue, up 11.1% year-over-year, surpassing expectations. 该公司将其2025年EPS准则提高到13.40至13.60美元,并宣布季度股息为每股0.84美元。 The company raised its 2025 EPS guidance to $13.40–$13.60 and declared a quarterly dividend of $0.84 per share. 包括1858年财富管理、Manitou投资管理、Sivik Global Healthcare以及Mitchell Sinkler & Starr在内的机构投资者增加了在医疗技术公司中的股份,该公司的市场上限为1 394.6亿美元,P/E比率为48.31。 Institutional investors including 1858 Wealth Management, Manitou Investment Management, Sivik Global Healthcare, and Mitchell Sinkler & Starr increased their stakes in the medical technology firm, which has a market cap of $139.46 billion and a P/E ratio of 48.31. 尽管内部销售,包括Ronda E. Stryker董事的一笔7 530万美元的交易,但股票仍维持一个协商一致的“Moderate Buy”评级,目标价格为430.10美元。 Despite insider sales, including a $75.3 million transaction by Director Ronda E. Stryker, the stock maintains a consensus “Moderate Buy” rating with a target price of $430.10.